Owing to its strong overexpression in prostate cancer and other urological cancers, the gastrin-releasing peptide receptor (GRPR) might represent a new therapeutic target. Here, the authors describe the role of the GRPR in normal physiology and summarize the available preclinical and early clinical data related to GRPR targeting in prostate and other urological cancers.
- Rosalba Mansi
- Achim Fleischmann
- Jean C. Reubi
